Next-Generation Antibodies Market To Be Worth $11.6bn In 2020, A New Visiongain Study Predicts

07 September 2018
Pharma

A new report by visiongain, published in April 2016, forecasts that the worldwide next-generation antibodies market will generate $11.6 billion in 2020. That revenue forecast and others appear in Next-Generation Antibody Therapies Market Forecast 2016-2026: Explore Developments and Sales Potentials for ADCs, Engineered Antibodies, ALPs, Bispecific and Biosimilar Agents.

Visiongain is a business information publisher and consultancy based in London, UK. Its purpose is to help companies and other organisations assess the potentials of industries and market in healthcare and other fields.

Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said:
“Next-generation antibody therapies are treatments based on antibodies that have been engineered or otherwise designed to have advantages over simple monoclonal antibodies. Next-generation antibodies are establishing themselves in the market, seven years after the current crop of novel therapies first reached the market with the approval of Kalbitor and Removab in 2009.

“Sales of Adcetris and Kadcyla constitute the majority of revenues in the market in 2016, but over the next ten years rapid growth will stem from the launch of biosimilar drugs, and later from new engineered and bispecific antibody therapies. A strong and varied R&D pipeline will propel this market to new heights from 2016 to 2026.”

First visiongain’s new study provides revenue forecasts to 2026 for five submarkets and the overarching world market:

• Antibody-drug conjugates
• Engineered antibodies
• Bispecific antibodies
• Antibody fragments and ALPs
• Biosimilar antibodies.

In addition that investigation shows revenue forecasts to 2026 for seven drugs:

• Adcetris
• Kadcyla
• Gazyva/Gazyvaro
• Poteligeo
• Removab
• Blincyto
• Kalbitor.

That analysis also shows revenue forecasts to 2026 for four regional markets:

• US
• EU5 group
• Asia-Pacific region
• Latin America
• Rest of the world.

The new report discusses forces stimulating sales growth over the next ten years, as well as forces restraining that industry and market. That work also shows interviews with three companies – Ablynx, arGEN-X and Mersana Therapeutics.

Next-Generation Antibody Therapies Market Forecast 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. Together those studies cover pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever